Acute Hepatic Porphyria Drugs Market - Top Companies and Manufacturers

Companies Dominating the Acute Hepatic Porphyria Treatment Landscape

The acute hepatic porphyria treatment market is dominated by market players such as Abbott Ltd. and Recordati Rare Diseases Inc. Moreover, several players in the pharmaceutical industry are increasingly expanding their product diversification by utilizing advanced healthcare technologies to develop treatment that would be suitable for all patients without causing any adverse side-effects on them. Additionally, market players are also hugely investing on research and developmental activities that would focus on treatment of rare diseases with the help of advancement in healthcare technologies.

Abbott Ltd.,

• Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis
• Recordati Rare Diseases Inc., and others.
• Teva Pharmaceutical Industries Ltd (Israel)
• Apotex Inc (Canada)
• Pfizer Inc (U.S.)
• H. Lundbeck A/S (Denmark)
• Lilly (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Siemens Healthcare GmbH (Germany)
• ACON Laboratories, Inc. (U.S.)